Current Research in Translational Medicine

Papers
(The TQCC of Current Research in Translational Medicine is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Anti-oxidant, antibacterial, anti-biofilm, and anti-quorum sensing activities of four essential oils against multidrug-resistant bacterial clinical isolates49
Machine learning and artificial intelligence in the service of medicine: Necessity or potentiality?45
Thoughts on cartilage tissue engineering: A 21st century perspective35
CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges27
A common TMPRSS2 variant has a protective effect against severe COVID-1926
Mechanistic insights into the role of pyroptosis in rheumatoid arthritis26
Role of Nrf2 in rheumatoid arthritis25
Role of HDAC inhibitors in diabetes mellitus23
Real world experience of approved chimeric antigen receptor T-cell therapies outside of clinical trials20
Age and vitamin D affect the magnitude of the antibody response to the first dose of the SARS-CoV-2 BNT162b2 vaccine19
Human mesenchymal stromal cells from different tissues exhibit unique responses to different inflammatory stimuli19
Sex-mediated effects of ACE2 and TMPRSS2 on the incidence and severity of COVID-19; The need for genetic implementation17
Metformin decreased myocardial fibrosis and apoptosis in hyperhomocysteinemia -induced cardiac hypertrophy15
A review of potential treatments to date in COVID-19 patients according to the stage of the disease15
Extracellular vesicles isolated from mesenchymal stromal cells primed with neurotrophic factors and signaling modifiers as potential therapeutics for neurodegenerative diseases14
Anti-TNF containing regimens may be associated with increased risk of Clostridioides difficile infection in patients with underlying inflammatory bowel disease14
Mesenchymal stem cells in the fight against viruses: Face to face with the invisible enemy14
Heparin beyond anti-coagulation14
Role and mechanism of LAIR-1 in the development of autoimmune diseases, tumors, and malaria: A review13
COVID-19 paraclinical diagnostic tools: Updates and future trends12
Astaxanthin attenuates acute cerebral infarction via Nrf-2/HO-1 pathway in rats10
Clinical prognosis evaluation of COVID-19 patients: An interpretable hybrid machine learning approach10
Cell therapy for prenatal repair of myelomeningocele: A systematic review10
European wide survey on allogeneic haematopoietic cell transplantation practice for myelofibrosis on behalf of the EBMT chronic malignancies working party9
IFNG-AS1 and MAF4 long non-coding RNAs are upregulated in acute leukemia patients who underwent bone marrow transplantation8
Preclinical study of a DNA vaccine targeting SARS-CoV-28
Allogeneic adipose-derived mesenchymal stromal cell transplantation for refractory lupus nephritis: Results of a phase I clinical trial7
Biological responses to COVID-19: Insights from physiological and blood biomarker profiles7
In utero treatment of myelomeningocele with allogenic umbilical cord-derived mesenchymal stromal cells in an ovine model7
CAR-T therapy in solid transplant recipients with post-transplant lymphoproliferative disease: case report and literature review7
Clinical determinants of relapse following CAR-T therapy for hematologic malignancies: Coupling active strategies to overcome therapeutic limitations7
Potential use of ivermectin for the treatment and prophylaxis of SARS-CoV-2 infection6
The use of intrathecal chemotherapy and dexamethasone for secondary prevention of blinatumomab-related neurotoxicity6
New scenarios in Vacuoles, E1 enzyme, X linked, Autoinflammatory, Somatic (VEXAS) syndrome: Evolution from myelodysplastic syndrome to acute myeloid leukemia6
Belumosudil with ROCK-2 inhibition: chemical and therapeutic development to FDA approval for the treatment of chronic graft-versus-host disease6
Identification of serum exosomal miR-98–5p, miR-183–5p, miR-323–3p and miR-19b-3p as potential biomarkers for glioblastoma patients and investigation of their mechanisms6
Is procalcitonin a part of human immunological response to SARS-CoV-2 infection or “just” a marker of bacterial coinfection?6
In silico assessment of binding affinities of three dementia-protective Human Leukocyte Antigen (HLA) alleles to nine human herpes virus antigens6
Selective dysregulation of ABC transporters in methotrexate-resistant leukemia T-cells can confer cross-resistance to cytarabine, vincristine and dexamethasone, but not doxorubicin6
Evaluation of Factor V Leiden and prothrombin G20210A mutations in Sudanese women with severe preeclampsia6
CAR-T cells targeting IL-1RAP produced in a closed semiautomatic system are ready for the first phase I clinical investigation in humans5
Comparison of mouse, rat and rabbit models for adipose - Derived stem cells (ASC) research5
Understanding the hematopoietic microenvironment in chronic myeloid leukemia: A concise review5
Cryopreserved allogeneic mesenchymal stem cells enhance wound repair in full thickness skin wound model and cattle clinical teat injuries4
Expression and survival analysis of the STAT gene family in diffuse gliomas using integrated bioinformatics4
A novel tumor inhibitory hybridoma monoclonal antibody with dual specificity for HER3 and HER24
Exosomal miR-195 in hUC-MSCs alleviates hypoxia-induced damage of trophoblast cells through tissue factor pathway inhibitor 24
Does Ibrutinib impact outcomes of viral infection by SARS-CoV-2 in mantle cell lymphoma patients?4
The influence of DNMT3A and DNMT3B gene polymorphisms on acute myeloid leukemia risk in a Moroccan population4
PHF19 inhibition as a therapeutic target in multiple myeloma4
Plasma-derived extracellular vesicles from myocardial infarction patients inhibits tumor necrosis factor-alpha induced cardiac cell death4
The concurrent administration of imatinib with extracorporeal photopheresis leads to complete and durable responses in patients with refractory sclerotic type chronic graft-versus-host disease4
0.031840801239014